TSLA

309.02

-0.22%↓

NKE

74.43

-0.6%↓

ORLY

102.26

+0.84%↑

HLT

260.19

-0.82%↓

AZO

4,012

+1.18%↑

TSLA

309.02

-0.22%↓

NKE

74.43

-0.6%↓

ORLY

102.26

+0.84%↑

HLT

260.19

-0.82%↓

AZO

4,012

+1.18%↑

TSLA

309.02

-0.22%↓

NKE

74.43

-0.6%↓

ORLY

102.26

+0.84%↑

HLT

260.19

-0.82%↓

AZO

4,012

+1.18%↑

TSLA

309.02

-0.22%↓

NKE

74.43

-0.6%↓

ORLY

102.26

+0.84%↑

HLT

260.19

-0.82%↓

AZO

4,012

+1.18%↑

TSLA

309.02

-0.22%↓

NKE

74.43

-0.6%↓

ORLY

102.26

+0.84%↑

HLT

260.19

-0.82%↓

AZO

4,012

+1.18%↑

Search

NVR Inc

Gesloten

SectorConsumenten cyclisch

7,927.46 1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7809.26

Max

7980.03

Belangrijke statistieken

By Trading Economics

Inkomsten

-158M

300M

Verkoop

198M

2.5B

K/W

Sectorgemiddelde

16.475

35.993

EPS

108.54

Winstmarge

12.746

Werknemers

7,000

EBITDA

4.8M

420M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+5.45% upside

Dividenden

By Dow Jones

Volgende Winsten

21 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

216M

22B

Vorige openingsprijs

7926.46

Vorige sluitingsprijs

7927.46

Nieuwssentiment

By Acuity

22%

78%

49 / 373 Rangschikking in Consumer cyclical

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

NVR Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2025, 21:42 UTC

Winsten
Acquisities, Fusies, Overnames

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 aug 2025, 21:21 UTC

Winsten
Belangrijke Marktbewegers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug 2025, 20:45 UTC

Winsten

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 aug 2025, 19:15 UTC

Belangrijke Marktbewegers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 aug 2025, 23:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 aug 2025, 23:41 UTC

Marktinformatie

Nikkei May Rise on Fed Stimulus Hopes

4 aug 2025, 23:28 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 aug 2025, 23:28 UTC

Marktinformatie

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 aug 2025, 21:30 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug 2025, 21:21 UTC

Winsten
Acquisities, Fusies, Overnames

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 aug 2025, 21:18 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug 2025, 20:25 UTC

Marktinformatie

India Hits Back Over Russian Oil Purchases -- Market Talk

4 aug 2025, 20:25 UTC

Winsten

Transocean 2Q Loss $938M >RIG

4 aug 2025, 20:25 UTC

Winsten

Transocean 2Q Loss/Shr $1.06 >RIG

4 aug 2025, 20:18 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 aug 2025, 20:15 UTC

Winsten

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 aug 2025, 20:13 UTC

Winsten

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 aug 2025, 20:09 UTC

Winsten

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 aug 2025, 20:06 UTC

Winsten

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 aug 2025, 19:41 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 aug 2025, 19:28 UTC

Marktinformatie

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 aug 2025, 19:07 UTC

Marktinformatie

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 aug 2025, 18:27 UTC

Marktinformatie

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer Vergelijking

Prijswijziging

NVR Inc Prognose

Koersdoel

By TipRanks

5.45% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8,183.33 USD  5.45%

Hoogste 8,800 USD

Laagste 7,600 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor NVR Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Technische score

By Trading Central

7007.57 / 7118.2Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

49 / 373 Rangschikking in Consumenten cyclisch

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over NVR Inc

NVR, Inc. operates as a homebuilder in the United States. The company operates through, Homebuilding and Mortgage Banking segments. It engages in the construction and sale of single-family detached homes, townhomes, and condominium buildings under the Ryan Homes, NVHomes, and Heartland Homes names. The company markets its Ryan Homes products to first-time and first-time move-up buyers; and NVHomes and Heartland Homes products to move-up and luxury buyers. It also provides various mortgage related services to its homebuilding customers, as well as brokers title insurance; performs title searches in connection with mortgage loan closings; and sells mortgage loans to investors in the secondary markets on a servicing released basis. The company primarily serves in Maryland, Virginia, West Virginia, Delaware, New Jersey, Eastern Pennsylvania, New York, Ohio, Western Pennsylvania, Indiana, Illinois, North Carolina, Georgia, South Carolina, Florida, Tennessee, and Washington, D.C. NVR, Inc. was founded in 1980 and is headquartered in Reston, Virginia.